Inhibitor of apoptosis protein‑like protein‑2: A novel growth accelerator for breast cancer cells

Zhu,Lin; Zhou,Weihua; Zhu,Xidi; Xiang,Siqi; Wang,Siyuan; Peng,Yingxia; Lu,Bangyun; Tang,Peizhi; Chen,Qian; Wu,Mengjuan; Peng,Xia; Chen,Ziyu; Sun,Ziyi; Yang,Kunliang; Xiang,Mingjun; Yu,Dandan

doi:10.3892/or.2018.6626

Inhibitor of apoptosis protein‑like protein‑2: A novel growth accelerator for breast cancer cells

Authors:
- Lin Zhu
- Weihua Zhou
- Xidi Zhu
- Siqi Xiang
- Siyuan Wang
- Yingxia Peng
- Bangyun Lu
- Peizhi Tang
- Qian Chen
- Mengjuan Wu
- Xia Peng
- Ziyu Chen
- Ziyi Sun
- Kunliang Yang
- Mingjun Xiang
- Dandan Yu
View Affiliations

Affiliations: Department of Biochemistry and Immunology, Medical Research Center, Institute of Medicine, Jishou University, Jishou, Hunan 416000, P.R. China, Department of Biochemistry and Immunology, Medical Research Center, Institute of Medicine, Jishou University, Jishou, Hunan 416000, P.R. China, Department of Bioengineering, Biological Science and Engineering School, North University of Nationalities, Yinchuan, Ningxia 750021, P.R. China, The First Affiliated Hospital, Institute of Medicine, Jishou University, Jishou, Hunan 416000, P.R. China, Tumor Hospital, Xiangxi Autonomous Prefecture, Jishou, Hunan 416000, P.R. China, The First Affiliated Hospital, Institute of Medicine, Jishou University, Jishou, Hunan 416000, P.R. China
Published online on: August 3, 2018 https://doi.org/10.3892/or.2018.6626
Pages: 2047-2055
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although the inhibitor of apoptosis protein‑like protein‑2 (ILP‑2) has been shown as a serological biomarker for breast cancer, its effect on breast cancer cell growth remains elusive. The present study aimed to determine the role of ILP‑2 in breast cancer cell growth. We used immunohistochemistry to analyze ILP‑2 expression in 59 tissue paraffin‑embedded blocks, which included 35 breast cancer tissues and 24 galactophore hyperplasia tissues. Western blot analysis was used to detect protein expression levels of ILP‑2 in breast cancer cell lines such as HCC‑1937, MX‑1 and MCF‑7 as well as breast gland cell line MCF 10A. ILP‑2 was silenced by siRNA in HCC‑1937, MX‑1 and MCF‑7 cell lines. MTT assays, scratch assays and AO‑EB double staining analysis were conducted to evidence the role of ILP‑2 on breast cancer cell growth. Results from this study showed increased ILP‑2 expression in breast cancer tissues and breast cancer cell lines such as HCC‑1937, MX‑1 and MCF‑7. Cell viability or rate of cell migration of HCC‑1937, MX‑1 and MCF‑7 cell lines was significantly inhibited when ILP‑2 was knocked down by siRNA. The apoptosis rate of HCC‑1937, MX‑1 and MCF‑7 cell lines was increased when compared with that of the control group. Thus, ILP‑2 plays an active role in the growth of breast cancer cells.

View Figures

View References

1	Lopez J and Meier P: To fight or die-inhibitor of apoptosis proteins at the crossroad of innate immunity and death. Curr Opin Cell Biol. 22:872–881. 2010. View Article : Google Scholar : PubMed/NCBI
2	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
3	de Almagro MC and Vucic D: The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy. Exp Oncol. 34:200–211. 2012.PubMed/NCBI
4	LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S and Korneluk RG: IAP-targeted therapies for cancer. Oncogene. 27:6252–6275. 2008. View Article : Google Scholar : PubMed/NCBI
5	Saleem M, Qadir MI, Perveen N and Ahmad B, Saleem U, Irshad T and Ahmad B: Inhibitors of apoptotic proteins: New targets for anticancer therapy. Chem Biol Drug Des. 82:243–251. 2013. View Article : Google Scholar : PubMed/NCBI
6	Liston P, Roy N, Tamai K, Lefebvre C, Baird S, Cherton-Horvat G, Farahani R, McLean M, Ikeda JE, MacKenzie A, et al: Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature. 379:349–353. 1996. View Article : Google Scholar : PubMed/NCBI
7	Hiscutt EL, Hill DS, Martin S, Kerr R, Harbottle A, Birch-Machin M, Redfern CP, Fulda S, Armstrong JL and Lovat PE: Targeting X-linked inhibitor of apoptosis protein to increase the efficacy of endoplasmic reticulum stress-induced apoptosis for melanoma therapy. J Invest Dermatol. 130:2250–2258. 2010. View Article : Google Scholar : PubMed/NCBI
8	Xiang M, Zhou W, Gao D, Fang X and Liu Q: Inhibitor of apoptosis protein-like protein-2 as a novel serological biomarker for breast cancer. Int J Mol Sci. 13:16737–16750. 2012. View Article : Google Scholar : PubMed/NCBI
9	Richter BW, Mir SS, Eiben LJ, Lewis J, Reffey SB, Frattini A, Tian L, Frank S, Youle RJ, Nelson DL, et al: Molecular cloning of ILP-2, a novel member of the inhibitor of apoptosis protein family. Mol Cell Biol. 21:4292–4301. 2001. View Article : Google Scholar : PubMed/NCBI
10	Wang L, Zhang Q, Liu B, Han M and Shan B: Challenge and promise: roles for Livin in progression and therapy of cancer. Mol Cancer Ther. 7:3661–3669. 2008. View Article : Google Scholar : PubMed/NCBI
11	Chuturgoon AA, Phulukdaree A and Moodley D: Fumonisin B₁ inhibits apoptosis in HepG2 cells by inducing Birc-8/ILP-2. Toxicol Lett. 235:67–74. 2015. View Article : Google Scholar : PubMed/NCBI
12	Han Y, Zhang L, Wang W, Li J and Song M: Livin promotes the progression and metastasis of breast cancer through the regulation of epithelial-mesenchymal transition via the p38/GSK3^β pathway. Oncol Rep. 38:3574–3582. 2017.PubMed/NCBI
13	Chen J, Xiao XQ, Deng CM, Su XS and Li GY: Downregulation of xIAP expression by small interfering RNA inhibits cellular viability and increases chemosensitivity to methotrexate in human hepatoma cell line HepG2. J Chemother. 18:525–531. 2006. View Article : Google Scholar : PubMed/NCBI
14	Buneker CK, Yu R, Deedigan L, Mohr A and Zwacka RM: IFN-^γ combined with targeting of XIAP leads to increased apoptosis-sensitisation of TRAIL resistant pancreatic carcinoma cells. Cancer Lett. 316:168–177. 2012. View Article : Google Scholar : PubMed/NCBI
15	Wang S, Bai L, Lu J, Liu L, Yang CY and Sun H: Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeutics. J Mammary Gland Biol Neoplasia. 17:217–228. 2012. View Article : Google Scholar : PubMed/NCBI
16	Liu H, Wang S, Sun H, Pan Z, Zhou W and Wu M: Inhibition of tumorigenesis and invasion of hepatocellular carcinoma by siRNA-mediated silencing of the livin gene. Mol Med Rep. 3:903–907. 2010.PubMed/NCBI
17	Wang TS, Ding QQ, Guo RH, Shen H, Sun J, Lu KH, You SH, Ge HM, Shu YQ and Liu P: Expression of livin in gastric cancer and induction of apoptosis in SGC-7901 cells by shRNA-mediated silencing of livin gene. Biomed Pharmacother. 64:333–338. 2010. View Article : Google Scholar : PubMed/NCBI
18	Dasgupta A, Alvarado CS, Xu Z and Findley HW: Expression and functional role of inhibitor-of-apoptosis protein livin (BIRC7) in neuroblastoma. Biochem Biophys Res Commun. 400:53–59. 2010. View Article : Google Scholar : PubMed/NCBI
19	Yang D, Song X, Zhang J, Ye L, Wang S, Che X, Wang J, Zhang Z and Wang L: Suppression of livin gene expression by siRNA leads to growth inhibition and apoptosis induction in human bladder cancer T24 cells. Biosci Biotechnol Biochem. 74:1039–1044. 2010. View Article : Google Scholar : PubMed/NCBI
20	Li CJ, Cong Y, Liu XZ, Zhou X, Shi X, Wu SJ, Zhou GX and Lu M: Research progress on the livin gene and osteosarcomas. Asian Pac J Cancer Prev. 15:8577–8579. 2014. View Article : Google Scholar : PubMed/NCBI